Skip to content

The Effect of Yogurt Containing BB12 on Children's Health and Child Care Absenteeism

The Effect of Daily Consumption of Yogurt Containing Bifidobacterium Lactis (BB12) on Children's' Health and Child Care Absenteeism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00653705
Enrollment
181
Registered
2008-04-07
Start date
2007-01-31
Completion date
2009-04-30
Last updated
2013-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childcare Absenteeism, Children's Health and Growth

Keywords

Probiotics, Children, Child Care Center, Nutrition, Health promotion

Brief summary

The aim of our study is to assess the effect of daily consumption of yogurt containing probiotic bacteria BB12 on the health and growth of healthy children 12-48 months of age in out of home child care.

Interventions

OTHERYogurt drink with probiotic bacteria BB12

Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.

OTHERPlacebo

Vanilla flavored dairy drink. One bottle a day for 16 weeks.

Sponsors

General Mills
CollaboratorINDUSTRY
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
12 Months to 48 Months
Healthy volunteers
Yes

Inclusion criteria

* An informed consent has been signed by the parents. * The child is at least one year old and has not had his 4th birthday at the beginning of the study * The child is healthy. * The child attends child care center at least 5 days a week, \> 4 hours per day.

Exclusion criteria

* Was born preterm. * Had a birth weight \<2,500 g. * Has congenital anomalies. * Has a structural abnormality of the digestive tract or previous significant gastrointestinal surgery. * Has chronic disease or malignancy. * Has a serious, unstable medical condition. * Is Failure to Thrive (FTT) (\<5th percentile of ideal body weight). * Has an allergy or atopic disease. * Has an allergy or intolerance to milk/dairy products. * Has an established diagnosis of lactase deficiency. * Is predisposed to infection (i.e., compromised immune system, HIV-AIDS, active bacterial disease, under steroid treatment). * Received antibiotic treatment or intentionally consumes probiotic products during the preceding 4 weeks. (If the subject was on antibiotics before the beginning of the study or probiotics, a washout period of 2 weeks is required.)

Design outcomes

Primary

MeasureTime frame
Days of illness symptoms, number, duration and severity of illness episodes, day care absenteeism, and parental work absenteeism16 weeks

Secondary

MeasureTime frame
Health care utilization and illness related costs as measured by number of physician visits, ER visits, hospitalizations, and antibiotics use. Also, child growth and quality of life. Exploratory biomarker outcomes in stool.16 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026